Goldman Sachs Group assumed coverage on shares of Odonate Therapeutics (NASDAQ:ODT) in a report published on Friday, The Fly reports. The brokerage issued a sell rating and a $26.00 price objective on the stock.
A number of other equities analysts have also recently issued reports on the company. ValuEngine cut Odonate Therapeutics from a hold rating to a sell rating in a report on Wednesday, October 2nd. Zacks Investment Research downgraded shares of Odonate Therapeutics from a buy rating to a hold rating in a research report on Tuesday, November 12th.
Shares of NASDAQ:ODT opened at $31.01 on Friday. Odonate Therapeutics has a 52-week low of $11.54 and a 52-week high of $43.75. The business’s 50 day simple moving average is $32.80 and its two-hundred day simple moving average is $31.11. The firm has a market cap of $994.92 million, a P/E ratio of -8.52 and a beta of 1.83.
Hedge funds and other institutional investors have recently modified their holdings of the company. Strs Ohio raised its holdings in shares of Odonate Therapeutics by 678.9% in the 2nd quarter. Strs Ohio now owns 14,800 shares of the company’s stock worth $543,000 after acquiring an additional 12,900 shares during the last quarter. Janus Henderson Group PLC raised its stake in shares of Odonate Therapeutics by 2.6% in the second quarter. Janus Henderson Group PLC now owns 1,315,426 shares of the company’s stock worth $48,262,000 after purchasing an additional 33,325 shares during the last quarter. TD Asset Management Inc. raised its stake in shares of Odonate Therapeutics by 57.2% in the second quarter. TD Asset Management Inc. now owns 28,393 shares of the company’s stock worth $1,042,000 after purchasing an additional 10,331 shares during the last quarter. Swiss National Bank bought a new position in shares of Odonate Therapeutics in the second quarter valued at approximately $455,000. Finally, Eagle Asset Management Inc. bought a new position in shares of Odonate Therapeutics in the second quarter valued at approximately $18,393,000. Hedge funds and other institutional investors own 98.04% of the company’s stock.
Odonate Therapeutics Company Profile
Odonate Therapeutics, Inc, a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with locally advanced or metastatic breast cancer. The company was founded in 2013 and is based in San Diego, California.
Further Reading: Gap Up Stocks
Receive News & Ratings for Odonate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odonate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.